COGT Cogent Biosciences Inc

Price (delayed)

$8.36

Market cap

$799.33M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.48

Enterprise value

$602.05M

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed ...

Highlights
The company's equity has surged by 89% YoY and by 64% QoQ
Cogent Biosciences's quick ratio has soared by 71% from the previous quarter and by 13% YoY
The company's net income fell by 43% YoY and by 10% QoQ
The EPS fell by 7% YoY and by 2.5% QoQ

Key stats

What are the main financial stats of COGT
Market
Shares outstanding
95.61M
Market cap
$799.33M
Enterprise value
$602.05M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.06
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$212.17M
EBITDA
-$208.24M
Free cash flow
-$168.4M
Per share
EPS
-$2.48
Free cash flow per share
-$1.78
Book value per share
$4.06
Revenue per share
$0
TBVPS
$5.02
Balance sheet
Total assets
$476.11M
Total liabilities
$53.78M
Debt
$18.52M
Equity
$422.33M
Working capital
$405.22M
Liquidity
Debt to equity
0.04
Current ratio
12.05
Quick ratio
11.88
Net debt/EBITDA
0.95
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-55.2%
Return on equity
-63.7%
Return on invested capital
-93.5%
Return on capital employed
-48.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

COGT stock price

How has the Cogent Biosciences stock price performed over time
Intraday
-1.65%
1 week
-6.9%
1 month
6.63%
1 year
-31.81%
YTD
42.18%
QTD
24.4%

Financial performance

How have Cogent Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$227.3M
Net income
-$212.17M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 43% YoY and by 10% QoQ
COGT's operating income is down by 42% year-on-year and by 9% since the previous quarter

Growth

What is Cogent Biosciences's growth rate over time

Valuation

What is Cogent Biosciences stock price valuation
P/E
N/A
P/B
2.06
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS fell by 7% YoY and by 2.5% QoQ
The company's equity has surged by 89% YoY and by 64% QoQ
The P/B is 14% above the 5-year quarterly average of 1.8 but 6% below the last 4 quarters average of 2.2

Efficiency

How efficient is Cogent Biosciences business performance
COGT's return on invested capital is up by 25% year-on-year and by 7% since the previous quarter
The ROA has contracted by 17% YoY but it has grown by 5% from the previous quarter
The company's return on equity fell by 17% YoY but it rose by 6% QoQ

Dividends

What is COGT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for COGT.

Financial health

How did Cogent Biosciences financials performed over time
Cogent Biosciences's total assets has surged by 81% YoY and by 52% QoQ
Cogent Biosciences's quick ratio has soared by 71% from the previous quarter and by 13% YoY
The company's debt is 96% lower than its equity
The company's equity has surged by 89% YoY and by 64% QoQ
Cogent Biosciences's debt to equity has shrunk by 56% YoY and by 43% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.